Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children-Reference-Cited by-同舟云学术

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Published:2013-04-30 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Andabaka Tea¹,Nickerson Jason W²,Rojas-Reyes Maria Ximena³,Rueda Juan David⁴,Bacic Vrca Vesna⁵,Barsic Bruno⁶

Affiliation:

1. Ewopharma Ltd; Zadarska 80 / 2 Zagreb Croatia 10000

2. Institute of Population Health; 1 Stewart Street Ottawa Ontario Canada K1N 6N5

3. Pontificia Universidad Javeriana; Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine; Cr. 7 #40-62, 2nd floor Bogota DC Colombia

4. Pontificia Universidad Javeriana; Departamento de Cirugía; Carrera 7 No. 40 - 62 Bogota Cundinamarca Colombia

5. University Hospital Dubrava; Department of Hospital Pharmacy; Avenija Gojka ?u?ka 6 Zagreb Croatia 10 000

6. University of Zagreb, School of Medicine, Hospital for Infectious Diseases; Department of Intensive Care; Mirogojska 8 Zagreb Croatia 10000

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006602.pub4/fullpdf

Reference112 articles.

1. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children;Abarca;Pediatric Infectious Disease Journal,2009

2. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK;Bentley;Thorax,2011

3. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a non-inferiority trial;Carbonell-Estrany;Pediatrics,2010

4. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants;Chirico;Italian Journal of Pediatrics,2009

5. Cost-efficacy analysis of palivizumab in the prevention of respiratory syncytial virus infections in young children with hemodynamically significant congenital heart disease;Chiroli;Italian Journal of Pediatrics,2005

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Disease: An Updated Systemic Review and Meta-Analysis;Cureus;2023-12-31

2. Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. Posicionamiento de la Sociedad Española de Infectología Pediátrica;Anales de Pediatría;2023-10

3. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP);Anales de Pediatría (English Edition);2023-10

4. Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus;Pathogens;2023-09-01

5. Respiratory Syncytial Virus: A Systematic Review and Meta-Analysis of Tomographic Findings (2000–2022);Children;2023-07-05